Key result
Sauchinone reduces cardiac hypertrophy, fibrosis, and dysfunction in preclinical models via TLR4 and CDK4 inhibition.
Why the study?
Does sauchinone reduce pathological cardiac hypertrophy and improve cardiac function in in vitro cardiomyocyte models and in vivo mouse models of hypertrophic cardiomyopathy and pressure overload?
Does sauchinone reduce pathological cardiac hypertrophy and improve cardiac function in in vitro cardiomyocyte models and in vivo mouse models of hypertrophic cardiomyopathy and pressure overload?
In preclinical cell and mouse models, sauchinone alleviates pathological cardiac hypertrophy and fibrosis by targeting the TLR4-NF-κB and CDK4-PI3K-Akt signaling pathways.
Answers are grounded in this paper and cite their sources.
No immediate clinical implications; leaves open therapeutic translation of sauchinone for human cardiac hypertrophy.
Pathological cardiac hypertrophy is a major contributor to heart failure and remains insufficiently targeted by current therapies that primarily focus on hemodynamic regulation rather than underlying molecular mechanisms. Sauchinone, a bioactive lignan isolated from Saururus chinensis, has been reported to exert anti-inflammatory and cardioprotective effects. However, its role in pathological cardiac hypertrophy and the associated mechanisms remain unclear. This study aimed to evaluate the therapeutic effect of sauchinone on pathological cardiac hypertrophy and to elucidate its potential mechanism. The H9c2, a rat cardiomyocyte cell line, along with human embryonic stem cells-derived cardiomyocytes (hESC-CMs), were employed to investigate the therapeutic potential of sauchinone on angiotensin II (Ang II)-induced hypertrophy in vitro. An established mouse model of hypertrophic cardiomyopathy (HCM) and transverse aortic constriction (TAC)-induced cardiac hypertrophy model were used for the animal studies. The investigation combined proteomics with molecular docking to explore the mechanisms by which sauchinone influences pathological cardiac hypertrophy. Sauchinone significantly attenuated cardiomyocyte hypertrophy, as evidenced by reduced cell size and decreased expression of hypertrophic markers in both H9c2 cells and hESC-CMs. In vivo, sauchinone markedly improved cardiac structure and function, reduced myocardial hypertrophy and fibrosis, and restored systolic and diastolic function in HCM and TAC mice. Mechanistically, quantitative proteomics and pathway enrichment analyses revealed that sauchinone significantly inhibited the PI3K-Akt and NF-κB signaling pathways, which was further confirmed by reduced phosphorylation of key pathway components. Notably, protein-protein interaction analysis, molecular docking, and target engagement assays demonstrated that sauchinone directly interacts with cyclin-dependent kinase 4 (CDK4) and Toll-like receptor 4 (TLR4), suggesting a dual-target mechanism. Collectively, these findings indicate that sauchinone alleviates pathological cardiac hypertrophy by coordinately suppressing inflammatory and growth signaling pathways via targeting the TLR4-NF-κB and CDK4-PI3K-Akt axes. Sauchinone may therefore represent a promising multi-target therapeutic candidate for the treatment of pathological cardiac hypertrophy.
No takes yet. Share an insight, caveat, or question.
Xu et al. (2026) studied Pathological cardiac hypertrophy and hypertrophic cardiomyopathy (HCM). Sauchinone was evaluated on Cardiomyocyte hypertrophy in vitro and cardiac structure, function, myocardial hypertrophy, and fibrosis in vivo. Sauchinone attenuated cardiomyocyte hypertrophy in vitro and reduced myocardial hypertrophy, fibrosis, and cardiac dysfunction in HCM and TAC mouse models via TLR4-NF-κB and CDK4-PI3K-Akt inhibition.
Synapse has enriched 10 related papers. Consider them for comparative context: